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OBJECTIVES: To examine prostate-speciﬁc antigen (PSA)
screening practice change in subgroups of men deﬁned in
guidelines and in various regions and to identify factors
associated with change in screening practices.
DESIGN: Observational study using serial cross-sections,
2003 to 2013.
SETTING: National fee-for-service Medicare.
PARTICIPANTS: Men aged 68 and older eligible for pros-
tate cancer screening.
MEASUREMENTS: National PSA screening practices in
men aged 68 and older from 2003 to 2013 and change in
regional screening rates in men aged 75 and older.
RESULTS: The PSA screening rate in men aged 68 and
older was 17.2% in 2003, 22.3% in 2008, and 18.6% in
2013 (p < .001 for all differences); rates ended slightly
lower than rates in 2003 only in men 80 and older. Racial
disparities in screening became less pronounced over this
period. In men aged 75 and older, change in regional
screening rates varied widely, with absolute rates growing
by 15 per 100 enrollees in some areas and declining by the
same amount in others. Areas with high social capital, a
measure associated with diffusion of new ideas, were more
likely to decline; malpractice intensity and managed care
penetration had no effect.
CONCLUSION: Studying Medicare enrollees over time, we
found little reduction in PSA screening and even increases
according to race and in some regions. The heterogeneous
changes across regions suggest that consistent reduction in
the use of low-value care may require change strategies that
go beyond evidence and guidelines to include monitoring and
feedback on performance. J Am Geriatr Soc 67:29–36, 2019.
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There is a “pervasive asymmetry in human psychology”that makes it harder for healthcare workers to give up
old clinical practices than to adopt new ones, even when they
are revealed to provide low value.1 Across disciplines, there is
increasing interest in the idea of “exnovation,” or the process
by which practitioners turn away from an existing practice or
process.2–5 Screening for prostate cancer using the prostate-
speciﬁc antigen (PSA) is an important example of evolution
of practice in response to emerging scientiﬁc evidence.
After years of debate, in March 2009, two randomized
controlled trials provided evidence that screening for prostate
cancer using the PSA test offered at best modest beneﬁts, par-
ticularly in aged 70 and older.6,7 In 2010 and 2011, system-
atic reviews concluded that PSA screening provides no
signiﬁcant reduction in prostate cancer or overall mortal-
ity.8,9 One concluded that the harms were frequent and mod-
erately severe,8 and the other found little evidence of harms.9
Before this period, guidelines for PSA screening repeat-
edly changed (Figure 1), converging on the notion that the
value of PSA screening is low. For example, when propos-
ing its latest update,10–14 the U.S. Preventive Services Task
Force (USPSTF) stated there is “a small net beneﬁt for men
ages 55 to 69 years, [but] the balance of beneﬁts and harms
in men remains close.”15 The guidelines are also nuanced,
requiring complex estimations of beneﬁt:harm ratios in sub-
groups of men who may not be well represented in trials.
For example, the USPSTF and the American Urological
Association have consistently recommended against screen-
ing men with a limited life expectancy, sometimes naming a
speciﬁc age cutpoint,16–21 and because of the greater risk of
From the *Department of Medicine, School of Medicine, University of
Michigan, Ann Arbor, Michigan; †Institute of Healthcare Policy and
Innovation, University of Michigan, Ann Arbor, Michigan; ‡Dartmouth
Institute for Health Policy and Clinical Practice, Geisel School of Medicine,
Dartmouth College, Hanover, New Hampshire; §Department of Economics,
Dartmouth College, Hanover, New Hampshire; and the ¶National Bureau
of Economic Research, Cambridge, Massachusetts.
Address correspondence to Julie Bynum, 300 North Ingalls, Rm 933, Ann
Arbor, MI 48109. E-mail: bynumju@med.umich.edu
DOI: 10.1111/jgs.15591
JAGS 67:29–36, 2019
© 2018, Copyright the Authors
Journal compilation © 2018, The American Geriatrics Society 0002-8614/18/$15.00
prostate cancer in black men, some guidelines recommend
initiating screening earlier.17,19,22
Changing guidelines were on a background of widely
varying regional screening practices. Given disparate screen-
ing practices, it is not clear that practice change, even for
the oldest men, for whom guidelines agreed, would occur
uniformly across markets. Examining what happened in
clinical practice over this period of evidence and guideline
change provides an opportunity to understand the process
of exnovation of low-value services.
Using PSA screening, we aimed to understand which
factors inﬂuence practice change during a period when a
decline in service use would be expected. First, we focused
on national PSA screening in men aged 68 and older with
fee-for-service Medicare from 2003 to 2013 and examine
the inﬂuence of guidelines by assessing changes in likeli-
hood of screening associated with factors directly men-
tioned in guidelines. Second, we focused on practice change
across U.S. hospital referral regions (HRRs) for men aged
75 and older – for whom guidelines have been in agreement
– to test whether practice variation declines and what con-
textual factors are associated with greater decline. We
hypothesized that guidelines and the practice environment
would inﬂuence the degree to which practitioners and
patients would reduce their use of an existing practice in
the face of converging evidence regarding effectiveness.
METHODS
Setting and Participants
This observational cohort study of older men was drawn
from a 20% national sample of the fee-for-service Medicare
population during each of 5 years: 2003, 2006, 2008,
2010, and 2013. Men were eligible if they were enrolled in
Medicare Parts A and B and not managed care. Because
PSA claims (identiﬁed using Common Procedural Terminol-
ogy codes 23) do not distinguish screening from diagnosis,
we applied an algorithm previously validated to exclude
men with any history of prostate disease (cancer, surgery,
high PSA) during the prior 3 years or symptoms suspicious
of cancer from visit diagnoses in the 3 months before a PSA
test.24,25 Men had to be aged 68 and older to accommodate
the disease-free interval. Men with no ambulatory visits
Figure 1. A history of clinical practice guidelines and evidence pertaining to prostate-speciﬁc antigen screening of asymptomatic
men, including all U.S. Protective Services Task Force guidelines, publication of pivotal evidence, and selected other guidelines.
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were excluded because it is unlikely that PSA levels tested
during hospitalization were for screening.
Information on age and race was obtained from the
Medicare summary ﬁle; information on covariates was
obtained also using claims information. Covariates included
dual eligibility for Medicaid, 10-year life expectancy as an
aggregate measure of illness that aligns with guideline rec-
ommendations, and visit patterns. We created predicted
10-year mortality risk scores. Logistic regression predicted
10-year mortality risk for the 2003 cohort – whose death
status was known at the end of 2012– using these explana-
tory variables: baseline age, race, Medicaid status, ambula-
tory visits, skilled nursing facility stays, and Elixhauser
comorbidity conditions. We used a random 50% sample to
derive our prediction model and the other half to validate it
(c-statistic=0.79 for both cohorts).26 Mean predicted mor-
tality ranged from 0.27 in the lowest quintile to 0.96 in
highest quintile. We included number and continuity of
ambulatory visits, which have been shown to inﬂuence
whether a person receives preventive services or low-value
care.27,28 We used the Continuity of Care Index, a compu-
tation of dispersion in visits across the number of unique
physicians, categorized into tertiles.29
HRRs to represent regional healthcare and were char-
acterized according to factors shown previously to inﬂuence
physician behavior: screening practice norms25 penetration
of managed care,30,31 malpractice activity,32 and social cap-
ital.33 We represent the underlying PSA screening practice
norm with the proportion of men aged 68 and 69 screened
because they were the only age group in our data who met
guidelines for potential beneﬁt.34,35 Malpractice activity,
which differs between areas,32 was measured according to
state according to physician payment amounts in 2003,
from which we created HRR measures weighted by the
fraction of each state’s residents. To account for potential
spill-over effects from practicing in an area where popula-
tion management strategies are prevalent,30,31 we measured
Medicare Advantage enrollment. Social capital measures
the multidimensional social environment that inﬂuences
behavior36 and has been associated with uptake of innova-
tions in- and outside medicine.33 A county-level social capi-
tal index is available for 2005 and 2009 based on the
number of civic, religious, and sports organizations per
capita; census response rate; voter turnout in presidential
elections; and number of nonproﬁt organizations per
capita.37 We weighted the county measures to the HRR
using Missouri Census Data Center Geographic Correspon-
dence Engine 2010 data.38
Statistical Analysis
Differences in the characteristics of the men in each cohort
year were tested using descriptive statistics. The large sam-
ple resulted in statistical signiﬁcance even when differences
were small. National trends are reported as crude screening
rate according to subgroup. The associations between age
and race adjusted for other factors including region in 2013
were compared with 2003. To do so, the probability of
having a PSA test was modeled using Poisson regression in
a hierarchical framework adjusting for regional effects using
a conditional likelihood approach. The Poisson model was
chosen because it allows estimation of relative risk when
event probability is high.39
Regional screening rates for men aged 75 and older in
each year were calculated using random-effects regression,
adjusting for population age, race, and predicted mortality.
The adjusted and crude rates were highly correlated (corre-
lation coefﬁcient = 0.99), so we report crude rates. We
tested whether variation in practice declined over time by
comparing the coefﬁcient of variation across HRRs from
2013 to 2003. We then modeled whether 2003 area charac-
teristics predicted absolute change in screening rate between
2003 and 2013. This study had institutional review board
approval from the Geisel School of Medicine. Analysis was
performed using SAS version 9.4 (SAS Institute, Inc., Cary,
NC) and Stata version 14.1 (Stata Corp., College Sta-
tion, TX).
RESULTS
Study Cohorts
Supplementary Figure S1 and Supplementary Table S1
show details of cohort creation and characteristics each
year. Approximately 40% of men each year were excluded
because of prostate disease, leaving approximately 1 million
men in each study-year eligible for a screening PSA. Over
time, mean age remained unchanged, but there were small
shifts in racial distribution, probability of death, Medicaid
enrollment, outpatient visits, and continuity. Penetration of
managed care increased from 16% to 35%.
Change in Screening According to Subgroups of Men
National PSA screening rates for men aged 68 and older
were 17.2% in 2003, rose to 22.3% in 2008, and declined
to 18.6% in 2013 (Figure 2). This trend was similar for all
race and age groups, including those aged 90 and older.
The screening rate in 2013, when the new trial and guide-
lines had been out for 1 to 5 years, remained 1.4% higher
than the screening rate in 2003. The 2013 screening rate
was slightly lower than in 2003 for men aged 80 to
84 (13.5% vs 14.1% p < .001), 85 to 89 (9.2% vs 10.3%,
p < .001), and 90 and older (5.8% vs 6.3%, p < .001). At
the beginning of the period, rates were lower for black and
Hispanic men than for white men but rose faster until
2008 such that by 2013 there was little if any racial
difference.
Bivariate analysis of proportions screened according to
individual characteristics is shown in Supplementary
Table S1. Using multivariable regression analysis control-
ling for region, we found independent effects of age, pre-
dicted mortality, race, dual eligibility, visits, and continuity,
although their inﬂuence changed over time. Figure 3 shows
these results graphically by comparing each factor’s
strength of association with likelihood of PSA screening in
2003 with the strength of association in 2013 (full model in
Supplementary Table S2). Predicted 10-year mortality was
consistently associated with lower likelihood of screening,
but age independent of life expectancy became important
over time. For example, in 2003, only men aged 90 and
older were at lower risk of being screened, but in 2013,
lower risk of screening was found beginning at age 75. This
JAGS JANUARY 2019–VOL. 67, NO. 1 CHANGE IN PSA SCREENING PRACTICES 31
ﬁnding suggests that age alone has become a deciding factor
in whether to screen.
The relationship between race and ethnicity and likeli-
hood of screening changed over time. Black race (relative
risk (RR) = 0.81, 95% conﬁdence interval (CI)=0.78–0.84)
and Hispanic ethnicity (RR = 0.86, 95% CI=0.78–0.94)
were associated with lower screening rates in 2003, but the
strength of association decreased for blacks (RR = 0.91,
95% .I=0.87–0.94) and became insigniﬁcant for Hispanics
(RR = 0.93, 95% CI=0.87–1.00) by 2013. As a result,
racial and ethnic disparities in screening rates declined dur-
ing this period. Dual-eligible enrollees, who were less likely
to be screened in 2003 (RR = 0.66, 95% CI= 0.63–0.70),
were not so in 2013 (RR = 0.93, 95% CI=0.82–1.02).
Finally, no change was seen in the relationship between visit
patterns and screening; having more ambulatory visits was
consistently associated with greater likelihood of screening
and greater continuity with slightly less likelihood of
screening.
Change in Screening Across Regions
In 2003, HRR rates of PSA screening varied widely for men
aged 75 and older, from 2.3% in Contra Costa County,
California, to 42.1% in Sun City, Arizona; the median was
14.1%, with a coefﬁcient of variation of 0.43. The coefﬁ-
cient of variation rose slightly to 0.49 in 2013, demonstrat-
ing greater practice variation.
Change in screening rates in men aged 75 and older
across regions was in an unanticipated direction, with
nearly as many HRRs experiencing a rise in screening as
experiencing a decline (Figure 4). Although the median
HRR declined by 1.5 percentage points, the screening rate
in some HRRs increased by as much as 15 percentage
points, whereas others declined by 15. Some HRRs declined
in every interval studied (42 HRRs, 14%), but increased in
14 after the trials were released. Higher level of screening at
baseline and higher social capital predicted decline in
screening. High proportion minority population predicted
rising rates (Supplementary Table S3). Other population
characteristics, malpractice activity, and penetration of
managed care were not consistently associated with change.
DISCUSSION
From 2003 to 2013, questions about the value of PSA
screening were reﬂected in guideline changes that new evi-
dence later supported. PSA screening in men aged 68 and
older, which had been rising, fell gradually from 2009 to
2013, after the trials were released, but still ended slightly
Figure 2. U.S. national rates for prostate-speciﬁc antigen (PSA) screening according to age and race for 2003 to 2013, when evi-
dence and clinical guidelines changed regarding PSA screening.
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higher in 2013 than in 2003. More surprisingly, we
observed an increase in regional variation for screening in
men aged 75 and older, suggesting more rather than less
divergence in clinical practice. Screening rates for men aged
75 and older increased during this period in nearly as many
HRRs as they decreased. Despite these variations, we found
evidence that guidelines had aggregate effects for some sub-
groups, such as a reduction in screening in those aged
Figure 3. Adjusted risk of prostate-speciﬁc antigen (PSA) Screening for men aged 68 and older associated with each individual fac-
tor in 2003 and 2013.
Figure 4. Variation across hospital referral regions in absolute change between 2003 and 2013 in prostate-speciﬁc antigen screen-
ing rate in men aged 75 and older.
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75 and older, and an attenuation of racial and ethnic dis-
parities, but those effects are modest compared with the
large variations in regional patterns of use.
Two recent reviews indicated that screening rates have
declined,40,41 but these reviews synthesized heterogeneous
data including self-reports (which have been shown to be
biased42), small areas, and different time periods. Two stud-
ies that used objective screening measures spanning 2008 to
2012 showed the same pattern as ours,43,44 whereas others
using shorter time periods or limited areas showed only
declining rates.45–50 We found no prior studies of change in
PSA screening rates in response to guidelines according to
race, although two studies found no differential effect of
race when examining referral or stage of disease.51,52 Our
study has the advantage over these prior studies of using
consistent measures of PSA testing well before and after evi-
dence change, with a large enough sample to examine het-
erogeneity of change across subgroups of men and across
areas. Unlike prior studies, by taking a longer view, we
found mixed evidence of the inﬂuence of guidelines: some
minor changes within named subgroups, but no large, con-
sistent shifts in practice toward less screening.
We did not expect to ﬁnd that PSA screening in men
aged 75 and older would increase in some regions, which
makes the analysis of contextual factors particularly impor-
tant. Our hypotheses were that factors might have affected
greater decline, such as average age in the region, income,
racial distribution, and contextual factors including malprac-
tice activity, prevalence of integrated healthcare, and social
capital. We found that average age and income were not
important, although higher minority population predicted
greater increase in screening, possibly due to efforts to reduce
disparities in access to care or in response to concerns about
higher prostate cancer risk. I light of the observed increase in
some areas, malpractice intensity was not a signiﬁcant pre-
dictor, nor was managed care penetration, but higher social
capital was. Social capital suggests that there is something in
the local culture that may make it more receptive to let go of
an existing practice. A similar association has been found for
uptake of new technologies such as beta blockers for acute
myocardial infarction but has not previously been shown in
association with exnovation.33
The modest reduction in screening rates in men aged
75 and older, who are more likely to experience harm than
beneﬁt from PSA screening, warrants asking why the evi-
dence and converging guidelines have done so little to
reduce low-value care. One reason could be discomfort with
age-based cut-points when age is only a proxy for life
expectancy. Life expectancy was the most important predic-
tor of screening in our data. With release of the age-based
recommendations, age alone was increasingly used as a
deciding factor. It is likely that the main challenge that
patients and providers face hinges less on the decision to
use age or life expectancy and more on having the time nec-
essary to make a well-informed decision that includes mor-
tality risk and time-to-beneﬁt considerations.53
Primary care providers, many of whom agree with the
guidelines54, are key players in changing screening practice
because of their role in cancer prevention and frequent
contact,55 but the evidence suggests that patients are
informed infrequently and that providers have not changed
their practice much.43,46,55 Change strategies that rely on
encouraging shared decision-making without providing
systematic support for the time those patient–provider
interactions require are unlikely to lead to wholesale
change in use of low-value care. Moreover, lack of feed-
back about a provider’s current performance precludes
the ability to evaluate and change one’s practice. Perfor-
mance reports regarding indicated services, such as diabe-
tes testing, are common but reporting on avoidance of a
service that is not recommended occurs less often. Our
results highlight the need, as alluded to previously,56 to
pay as much attention to evaluating changes in our prac-
tice when incorporating new evidence as on developing
and evaluating the evidence itself.
What can we learn generally from this study about
reducing the use of an existing practice? First, when guide-
lines recommend discontinuing a service, the response may
be slower than when adding or increasing use is recom-
mended. Second, when guidelines change multiple times
and require a nuanced decision process, they may not meet
with uniform adoption. During the early period of obser-
vation, when guidelines indicated doubt about PSA value
while trials were pending, rates of screening rose. One
explanation could be that publicity about the controversial
recommendations led to greater attention and hence use.
Third, fragmented physician contact increased the likeli-
hood of a man having PSA screening. Greater continuity
may relate to greater patient–physician trust when making
a difﬁcult decision to reduce use. Lastly, although the
social capital of an area is not in itself modiﬁable, aware-
ness of this community factor allows policy and clinical
leaders to anticipate where adoption may be rapid and
other areas where a more active change strategy may be
needed.
There are several limitations of the study. We cannot
discern who is driving the change in practice: patients or pro-
viders, but there were no changes in Medicare coverage of
PSA screening, which eliminates patient cost as a potential
explanation.57 This limitation raises the important point that
an additional approach to changing low-value practice is
through consumer-directed efforts. Second, our study is
restricted to the fee-for-service Medicare population, so
results may not be generalizable to the managed care setting.
Summary
Screening for prostate cancer serves as an excellent case
study of how exnovation occurs, or does not, when evi-
dence and guidelines suggest use should decline. Studying
Medicare enrollees over time, we found little reduction
and even increases according to race and in some regions.
The presumption that better clinical evidence and guide-
lines alone will lead to a signiﬁcant reduction in use of
potentially low-value care may be overly optimistic, espe-
cially when the recommendations require nuanced appli-
cation. Messaging that prioritizes potential beneﬁt in one
subgroup risks overdiagnosis and overtreatment when
that message is generalized. In addition to careful guide-
line messaging, attaining better evidence-driven, person-
centered care may require more-systematic approaches
that include local monitoring of and feedback on behav-
iors we aim to reduce.
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